drugset / Trial / NCT00999817

A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers

NCT00999817

Phase 1 Completed 14 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

A study to study the potential effect of PF-00299804 inhibition of CYP2D6 on dextromethorphan.

Timeline

Start
2009-11
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DACOMITINIB ANHYDROUS Small molecule 45 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral

Indications

No indication recorded.